- Home
- ORKA vs OPK Comparison
ORKA vs OPK Comparison
Compare ORKA & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORKA
- OPK
- Stock Information
- Founded
- ORKA 2004
- OPK 2007
- Country
- ORKA United States
- OPK United States
- Employees
- ORKA N/A
- OPK N/A
- Industry
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- OPK Biotechnology: Pharmaceutical Preparations
- Sector
- ORKA Health Care
- OPK Health Care
- Exchange
- ORKA Nasdaq
- OPK Nasdaq
- Market Cap
- ORKA 580.3M
- OPK 1.0B
- IPO Year
- ORKA N/A
- OPK 1995
- Fundamental
- Price
- ORKA $16.21
- OPK $1.39
- Analyst Decision
- ORKA Strong Buy
- OPK Buy
- Analyst Count
- ORKA 6
- OPK 4
- Target Price
- ORKA $40.83
- OPK $2.75
- AVG Volume (30 Days)
- ORKA 190.4K
- OPK 2.0M
- Earning Date
- ORKA 11-12-2025
- OPK 11-06-2025
- Dividend Yield
- ORKA N/A
- OPK N/A
- EPS Growth
- ORKA N/A
- OPK N/A
- EPS
- ORKA N/A
- OPK N/A
- Revenue
- ORKA N/A
- OPK $664,029,000.00
- Revenue This Year
- ORKA N/A
- OPK N/A
- Revenue Next Year
- ORKA N/A
- OPK $0.84
- P/E Ratio
- ORKA N/A
- OPK N/A
- Revenue Growth
- ORKA N/A
- OPK N/A
- 52 Week Low
- ORKA $5.49
- OPK $1.11
- 52 Week High
- ORKA $31.13
- OPK $2.04
- Technical
- Relative Strength Index (RSI)
- ORKA 57.56
- OPK 51.88
- Support Level
- ORKA $14.67
- OPK $1.34
- Resistance Level
- ORKA $16.21
- OPK $1.44
- Average True Range (ATR)
- ORKA 1.09
- OPK 0.04
- MACD
- ORKA -0.04
- OPK -0.00
- Stochastic Oscillator
- ORKA 41.13
- OPK 50.00
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
About OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.